 Prior to Week 8 subjects will not be allowed to increase or decrease Crohns specific concomitant medications except in the event of concomitant Crohns treatment-related toxicities assessed as moderate to severe. Changes in concomitant medications atafter Week 8 will be at the Investigators discretion. 